March 20, 2019 / 12:23 AM / 4 months ago

AbbVie hit with antitrust lawsuit over Humira 'patent thicket'

AbbVie Inc used a dense web of 100-plus patents to insulate its blockbuster drug Humira from U.S. competition while cutting deals with rivals that delayed the release of cheaper biosimilar versions, according to a proposed antitrust class action lawsuit.

The lawsuit, filed on Monday in Chicago federal court, accused AbbVie’s of using a so-called “patent thicket” to maintain a monopoly over the $20-billion-a-year drug, which is used to treat arthritis and other diseases and sells in the United States at ever-increasing prices.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below